Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: A policy statement from the American Association for Cancer Research

Clinical Cancer Research

Volumn 20, Issue 19, 2014, Pages 4978-4981

  Sawyers, Charles L ^a   Van 't Veer, Laura J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB;

ARTICLE; CANCER PATIENT; CANCER RESEARCH; GENE MUTATION; GENOMICS; HEALTH CARE; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PROTEOMICS; RELIABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH SERVICE; LEGISLATION AND JURISPRUDENCE; NEOPLASMS; PROCEDURES; STANDARDS; UNITED STATES;

DELIVERY OF HEALTH CARE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VOLUNTARY HEALTH AGENCIES;

EID: 84908428406     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2295     Document Type: Article

References (10)

1. US Food and Drug Administration. Crizotinib accelerated approval letter; accessed on Aug 5, 2014 http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/202570s000ltr.pdf.
2. US Food and Drug Administration. Vemurafenib approval package; accessed on Aug 5, 2014 http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/202429Orig1s000Approv.pdf.
3. US Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools); accessed on Aug 5, 2014 http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
4. Transforming cancer care through diagnostics and personalized medicine- Agenda of symposium sponsored by AACR and AdvaMedDx; accessed on Aug 5, 2014 http://www.aacr.org/Advocacy-Policy/GovernmentAffairs/Pages/aacr-advameddx-symposium-on-cancer-diagnostics-agenda-EF0C4F.aspx.
5. Transforming cancer care through diagnostics and personalized medicine-symposium sponsored by AACR and AdvaMedDx; video archive of the event; accessed on Aug 5, 2014 http://www.youtube.com/playlist?feature=edit-ok&list=PLBR9hdykU9fZQpJGvd9IFvXyAYgln2ON0.
6. IOM (Institute of Medicine). 2012. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: The National Academies Press.
7. Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014;20:1428-44.
8. Centers for Medicare and Medicaid Services. Clinical Laboratory Improvements Amendments accessed on Aug 5, 2014. http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/LDT-and-CLIA-FAQs.pdf.
9. US Food and Drug Administration. Notification to Congress and Anticipated details of the draft guidance to industry, Food and Drug Administration Staff and Clinical Laboratories, Framework for regulatory oversight of Laboratory Developed Tests (LDTs); accessed on Aug. 5, 2014 http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/UCM407409.pdf.
10. Buchen L. Cancer: missing the mark. Nature 2011;471:428-32.